secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001104659-23-083425
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion provides corporate presentation; no material new financial or clinical data
--------------------------------------------------------------------------------

- Rencofilstat Phase 2b ASCEND-NASH enrolling; AI-POWR platform highlighted.
- Phase 2a HCC trial pending; rencofilstat tested in over 425 subjects to date.
- Cash of $43.0M as of March 31, 2023; IP extends to at least 2031 with PTE.
- Core team previously developed voclosporin (Lupkynis) for lupus nephritis.
- Presentation details pipeline, finance, and management; no new clinical results disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000110465923083425/0001104659-23-083425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000110465923083425/tm2321697d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-083425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer